BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Drug Development

  Inovio Pharmaceuticals Begins Phase Ib/II Cancer Efficacy Trial Combining Its T-cell Immunotherapy with a PD-L1 Checkpoint Inhibitor in Advanced Bladder Cancer

  Inovio announced initiation of a phase 1b/2 immuno-oncology trial to evaluate Genentech/Roche’s atezolizumab in combination with Inovio’s INO-5401 and INO-9012.

  October 16, 2017

   · 

  7 min read
• Drug Development

  Mithra Announces Completion Of Recruitment In Donesta Phase II Study

  Mithra, a company specialized in Women’s Health, today announces the completion of recruitment in the E4 Relief Phase II study of Donesta.

  October 16, 2017

   · 

  5 min read
• Genetown

  Akcea Presents Data Demonstrating Significant Burden of Illness in Familial Chylomicronemia Syndrome

  New data from the global IN-FOCUS study were presented at the NORD Rare Diseases and Orphan Products Breakthrough Summit in Washington, D.C.

  October 16, 2017

   · 

  5 min read
• Business

  Dentsply Sirona Announces Additions to Executive Leadership Team

  Dentsply Sirona announced the appointment of two new Executive Leadership Team members, effective immediately.

  October 16, 2017

   · 

  5 min read
• Drug Development

  Karolinska Development’s Portfolio Company Aprea Announces First Patient Enrolled In Clinical Phase Ib/II Study With APR-246 For The Treatment Of Esophageal Cancer

  Karolinska Development today announces that the portfolio company Aprea Therapeutics AB has enrolled the first patient in a Phase 1b/2 study with the drug candidate APR-246 for the treatment of esophageal cancer.

  October 16, 2017

   · 

  2 min read
• Novo Nordisk - Share Repurchase Programme

  Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR).

  October 16, 2017

   · 

  1 min read
• BGB324, BerGenBio’s Selective First-in-Class AXL Inhibitor, Featured in 3 Clinical Presentations At 18th World Conference On Lung Cancer In Yokohama

  BerGenBio announces presentations on three ongoing Phase 2 clinical trials with BGB324 in lung cancer patients at the 18th World Conference on Lung Cancer in Yokohama, Japan.

  October 16, 2017

   · 

  6 min read
• Biotech Beach

  REVA Announces Commercial Expansion and the First Implant of the Fantom Bioresorbable Scaffold in Switzerland

  REVA Medical announced the commercial expansion of its bioresorbable scaffold (“BRS”), Fantom, with the first implant in Switzerland.

  October 16, 2017

   · 

  3 min read
• Biotech Beach

  Biotech Holdings Announces Effective Induction of “Reverse Abscopal Effect” in Rheumatoid Arthritis Using Procell Activated Stem Cells

  Biotech Holdings announced today filing of a patent application entitled “Reverse Abscopal Effect for Treatment of Autoimmunity.”

  October 16, 2017

   · 

  2 min read
• Drug Development

  Fennec Announces Positive Results From Phase III SIOPEL 6 Study on PEDMARK™ (sodium thiosulfate) Presented at the 49th Congress of the International Society of Pediatric Oncology 2017 Meeting

  The SIOPEL 6 study met its primary endpoint.

  October 16, 2017

   · 

  7 min read